Brief: Ascentage Pharma Says BCR-ABL Inhibitor In China Recommended For Breakthrough Therapy Designation
24/03/2021 11:24
March 24 (Reuters) - Ascentage Pharma Group International
6855.HK :
* UNIT'S BCR-ABL INHIBITOR IN CHINA OLVEREMBATINIB
RECOMMENDED FOR
BREAKTHROUGH THERAPY DESIGNATION
Source text https://www1.hkexnews.hk/listedco/listconews/sehk/2021/0324/2021032400950.pdf
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up